Alzheimer’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
The Alzheimer’s Disease therapeutics market is entering a period of significant expansion, supported by advances in disease-modifying treatments and the growing approval of anti-Aβ monoclonal antibodies. As treatment innovation accelerates and diagnosis improves, the market is poised for substantial long-term growth across major global healthcare systems.
GlobalData estimates that the Alzheimer’s Disease (AD) market across the eight major markets (8MM)—the US, France, Germany, Italy, Spain, the UK, Japan, and China—was valued at $2.4 billion in 2023. The market encompasses sales of both symptomatic therapies and disease-modifying treatments, reflecting the evolving treatment landscape.
The US and China dominate global sales, contributing $1.1 billion (44.7%) and $915.2 million (38.8%), respectively. At the other end of the spectrum, France represents the smallest share at 1.1%, influenced by a lower prevalent population and the absence of reimbursement for current symptomatic therapies, resulting in reduced treatment rates. By 2033, the AD market across the 8MM is projected to reach $17.0 billion, growing at a compound annual growth rate (CAGR) of 21.8%.
Scope
This report provides a comprehensive analysis of the Alzheimer’s Disease therapeutics market across the eight major markets, supported by an Excel-based forecast model extending through 2033. Coverage includes:
Overview of Alzheimer’s Disease, including epidemiology, symptoms, diagnosis, and disease management
Annualized therapeutics market revenue forecasts from 2023 to 2033
Analysis of cost of therapy per patient and treatment usage patterns
Strategic competitor assessment and overall market characterization
Identification of unmet needs within the Alzheimer’s treatment landscape
Clinical trial mapping and analysis of its implications for the therapeutics market
Comprehensive pipeline analysis evaluating emerging trends and mechanisms of action under development
Profiles of the most promising late-stage candidates
Assessment of current and future competition within the global Alzheimer’s Disease therapeutics market
Detailed review of key industry drivers, restraints, and challenges, with qualitative analysis of their market implications
How industry leaders are using this report
Develop in-licensing and out-licensing strategies by evaluating pipeline products, technologies, and companies with strong development portfolios
Build business strategies by understanding the trends shaping the 8MM Alzheimer’s Disease therapeutics market
Identify innovative products, technologies, and companies likely to influence future market dynamics
Formulate effective sales and marketing strategies using competitive landscape analysis and performance benchmarking
Detect emerging players with potentially strong product portfolios and create counter-strategies
Prioritize market segments presenting the greatest opportunities for investment, consolidation, and strategic partnerships
Reasons to Buy
Develop and design in-licensing and out-licensing strategies through detailed pipeline analysis
Understand the major trends driving growth in the 8MM Alzheimer’s Disease therapeutics market
Drive revenue opportunities by identifying innovative products, technologies, and high-impact companies
Strengthen sales and marketing strategies through competitive intelligence
Gain visibility into emerging competitors and evolving product portfolios
Identify high-opportunity market segments for investments and partnerships
Who should buy this report
Pharmaceutical and Biopharmaceutical Companies
Alzheimer’s and CNS Therapeutics Developers
Business Development and Licensing Teams
Commercial Strategy and Market Intelligence Functions
Healthcare Investors and Strategic Partnerships Teams
Consultants and Industry Advisors
Otsuka Pharmaceutical Co Ltd
Novartis AG
Biogen Inc
Eisai Co Ltd
Suven Life Sciences Ltd
Towa Pharmaceutical Co Ltd
AB Science SA
H. Lundbeck AS
Neurimmune Holding AG
Annovis Bio Inc
Teikoku Seiyaku Co Ltd
AbbVie Inc
BioVie Inc
Alzheon Inc
Axsome Therapeutics Inc
TauRx Pharmaceuticals Ltd
Anavex Life Sciences Corp
Shanghai Green Valley Pharmaceutical Co Ltd
Johnson & Johnson
Corium LLC
Bristol-Myers Squibb Co
Ono Pharmaceutical Co Ltd
Novo Nordisk AS
Daiichi Sankyo Co Ltd
AriBio Co Ltd
Luye Pharma Group Ltd
BioXcel Therapeutics Inc
AlphaCognition Inc
Biomed Industries Inc
Cerecin Inc
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Alzheimer's Disease reports